2022: A pivotal year for diagnosis and treatment of rare genetic diseases
Molecular Case Studies · 25.02.2022 · mcs.a006204
DOI: 10.1101/mcs.a006204 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Case Studies, online erschienen am 25.02.2022. Verfasst von Stephen F Kingsmore. Beteiligte Einrichtung: Rady Children's Institute for Genomic Medicine, Rady Children's Hospital, San Diego, California 92123, USA; Keck Graduate Institute, Claremont Colleg…. Hauptthemen laut MEDLINE: Rare Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS.
Abstract (Originalsprache)
The start of 2022 is an inflection point in the development of diagnostics and treatments for rare genetic diseases in prenatal, pediatric, and adult individuals; the theme of this special issue. Here I briefly review recent developments in the latter two aspects of rare genetic disease diagnostics and treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Rady Children's Institute for Genomic Medicine, Rady Children's Hospital, San Diego, California 92123, USA; Keck Graduate Institute, Claremont Colleges, Claremont, California 91711, USA.
ORCID-Profile: Stephen F Kingsmore
Förderung
- NICHD NIH HHS
Zitieren
APA
Kingsmore, S. F. (2022). 2022: A pivotal year for diagnosis and treatment of rare genetic diseases. Molecular Case Studies, mcs.a006204. https://doi.org/10.1101/mcs.a006204
Vancouver
Kingsmore SF. 2022: A pivotal year for diagnosis and treatment of rare genetic diseases. Molecular Case Studies. 2022:mcs.a006204. doi:10.1101/mcs.a006204
BibTeX
@article{Kingsmore2022,
author = {Kingsmore, Stephen F},
title = {2022: A pivotal year for diagnosis and treatment of rare genetic diseases},
journal = {Molecular Case Studies},
year = {2022},
pages = {mcs.a006204},
doi = {10.1101/mcs.a006204}
}
EUVIMED